Guardant Health, Inc. (GH)
Guardant Health, Inc. brought in $1.3B of revenue over the twelve months to September 30, 2026, up 41.7% from a year earlier. It posted a net loss of $485.1M. In fiscal 2025 capital spending exceeded operating cash flow by $233.1M. At September 30, 2026 it held $1B in cash against $1.5B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Guardant Health, Inc.
- Net worth
- Guardant Health, Inc. has a market value (market cap) of $20.8B at the latest share price, and shareholders' equity of -$275.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $982M (+32.9% year on year), with a net loss of $416.3M. Over the 12 months to September 30, 2026: revenue $1.3B, net loss $485.1M.
- Cash flow
- In fiscal 2025 operations used $184.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Guardant Health, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Guardant Health, Inc. does
Guardant Health, Inc. is registered with the SEC under industry code SIC 8071 (Services-Medical Laboratories). Its shares trade on NASDAQ under the ticker GH.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $982M | -$416.3M | -$3.32 | -$233.1M |
| 2024 | $739M | -$436.4M | -$3.56 | -$274.9M |
| 2023 | $563.9M | -$479.4M | -$4.28 | -$345.5M |
| 2022 | $449.5M | -$654.6M | -$6.41 | -$386.9M |
| 2021 | $373.7M | -$384.8M | -$4.00 | -$284.1M |
| 2020 | $286.7M | -$253.8M | -$2.60 | -$140.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where GH ranks in Health care
Latest SEC filings
What Guardant Health, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 36% to $361M versus the same quarter last year; diluted EPS -$0.93 versus -$0.74.
- November 5, 2026
- November 5, 2026Passive stake (5% or more) SCHEDULE 13G
- November 3, 2026
- November 3, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- July 30, 2026
- July 30, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 44% to $335M versus the same quarter last year; diluted EPS -$0.90 versus -$0.80.
- July 30, 2026
- July 28, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Guardant Health, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $9.7M worth of shares in the last 90 days and bought none on the open market. 2% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 21, 2026 | Mignone RobertoDirector | Exercised options | 264 | - |
| October 17, 2026 | Hidalgo Medina ManuelDirector | Exercised options | 232 | - |
| October 16, 2026 | Tariq MusaDirector | Soldpre-planned (10b5-1) | 116 | $19.2K |
| October 15, 2026 | Tariq MusaDirector | Exercised options | 250 | - |
| October 14, 2026 | Azar Alex M IIDirector | Soldpre-planned (10b5-1) | 69 | $11K |
| October 12, 2026 | Azar Alex M IIDirector | Exercised options | 137 | - |
| October 1, 2026 | Monroe Terilyn J.Chief People Officer | Exercised options | 2,659 | - |
| October 1, 2026 | Monroe Terilyn J.Chief People Officer | Exercised options | 1,360 | - |
Who owns GH
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 5.8% | November 5, 2026 |
| Vanguard Capital Management13G, passive | 5.02% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 597 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 7,622,935 | -3,930,824 |
| Vanguard Capital Management LLC | 5,755,857 | +131,677 |
| Fmr LLC | 5,488,272 | +1,372,191 |
| Vanguard Portfolio Management LLC | 5,445,785 | -392,207 |
| Invesco Ltd. | 4,429,755 | -516,714 |
| Goldman Sachs Group Inc | 3,775,895 | -659,944 |
| Two Sigma Investments, LP | 3,719,301 | -510,230 |
| Capital International Investors | 3,399,604 | -81,714 |
| Deep Track Capital, LP | 3,393,312 | +55,071 |
| Franklin Resources Inc | 3,236,065 | -212,128 |
| Ameriprise Financial Inc | 3,150,897 | +1,736,011 |
| Fuller & Thaler Asset Management, Inc. | 2,629,007 | +78,693 |
| Geode Capital Management, LLC | 2,521,596 | -987,287 |
| Baillie Gifford & Co | 2,284,127 | -1,574,919 |
| State Street Corp | 2,263,504 | -621,116 |
| Federated Hermes, Inc. | 1,999,178 | +111,594 |
| Eventide Asset Management, LLC | 1,957,828 | -404,551 |
| Jane Street Group, LLC | 1,783,444 | +1,778,641 |
| Westfield Capital Management Co LP | 1,624,459 | +261,920 |
| Millennium Management LLC | 1,622,458 | +701,063 |
Insiders
18 insiders reported holding 4,341,015 shares in total, about $674.4M at the last price.
| Holder | Shares |
|---|---|
| Eltoukhy HelmyCo-Chief Executive Officer, Director | 1,958,9491,958,949 held indirectly |
| Talasaz AmirAliCo-Chief Executive Officer, Director | 1,842,3661,842,366 held indirectly |
| Chudova DaryaChief Technology Officer | 128,82854,480 held indirectly |
| Eagle CraigChief Medical Officer | 72,001 |
| Freeman ChrisChief Commercial Officer | 69,647 |
| Bell Michael BrianChief Financial Officer | 55,182 |
| Kalia KumudChief Information Officer | 42,773 |
| Saia John G.Chief Legal Officer | 42,348 |
| Gadde VijayaDirector | 28,517 |
| Monroe Terilyn J.Chief People Officer | 24,900 |
Questions about GH
What does Guardant Health, Inc. do?
Guardant Health, Inc. is a company in the Health care sector, listed on NASDAQ as GH. Its shares trade on NASDAQ under the ticker GH.
What is Guardant Health, Inc.'s net worth?
Guardant Health, Inc. has a market value (market cap) of $20.8B at the latest share price, and shareholders' equity of -$275.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Guardant Health, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $485.1M on revenue of $1.3B.
How much revenue does Guardant Health, Inc. make?
Over the twelve months to September 30, 2026 Guardant Health, Inc. reported revenue of $1.3B. That is 41.7% more than a year earlier.
When did Guardant Health, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Guardant Health, Inc.'s next earnings report?
Guardant Health, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare GH with
Follow GH
Get an email when Guardant Health, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Guardant Health, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.